OVID Stock Summary and Trading Ideas (Ovid Therapeutics | NASDAQ:OVID)

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.

Ovid Therapeutics trades on the NASDAQ stock market under the symbol OVID.

As of January 15, 2026, OVID stock price declined to $1.59 with 1,186,359 million shares trading.

OVID has a beta of 2.26, meaning it tends to be more sensitive to market movements. OVID has a correlation of 0.12 to the broad based SPY ETF.

OVID has a market cap of $113.23 million. This is considered a Micro Cap stock.

Last quarter Ovid Therapeutics reported $132,000 in Revenue and -$.17 earnings per share. This fell short of revenue expectation by $-106,228 and missed earnings estimates by -$.02.

In the last 3 years, OVID traded as high as $4.14 and as low as $.24.

The top ETF exchange traded funds that OVID belongs to (by Net Assets): VTI, VXF, BSVO, QQQS.

OVID has outperformed the market in the last year with a return of +108.7%, while the SPY ETF gained +18.0%. However, in the most recent history, OVID shares have underperformed the stock market with its stock returning -3.6% in the last 3 month period and -2.5% for the last 2 week period, while SPY has returned +4.4% and +1.5%, respectively.

OVID support price is $1.55 and resistance is $1.75 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OVID shares will trade within this expected range on the day.